Related Experiment Video
Updated: Jul 1, 2026

A Protocol for Transcranial Photobiomodulation Therapy in Mice
Published on: November 18, 2018
Near‑Infrared Photobiomodulation in White‑Matter Disease: From Microglial States to Measurable Endpoints
Jiahao Zhang1, Quanguang Zhang1, J Dedrick Jordan2
1Institute for Cerebrovascular and Neuroregeneration Research (ICNR), Department of Neurology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA, 71103, USA.
Abstract:
White-matter (WM) injury contributes to disability across multiple sclerosis, traumatic brain injury, Alzheimer's disease and related dementias, and small-vessel disease. We use microglial state programs as an organizing axis for WM injury-to-repair logic, while emphasizing that WM outcomes are multicellular and involve oligodendrocyte-lineage cells, astrocytes, axons/neurons, and vascular factors. Microglia span an injury-repair continuum, from inflammatory programs that increase oxidative stress and debris burden to repair-competent programs that support debris handling, remyelination, and axonal integrity. Near-infrared photobiomodulation (PBM; ~800-1100 nm) is most consistently associated with modulation of mitochondrial redox/bioenergetic pathways and inflammatory tone. CCO-centered mechanistic framing is best established near ~ 800-850 nm, whereas longer wavelengths (e.g., ~ 1064-1070 nm) may involve additional initiating mechanisms with downstream convergence on shared redox/bioenergetic and inflammatory pathways. Across demyelination and spinal cord injury models, appropriately dosed PBM has been reported to reduce inflammatory glial readouts and to associate with improved myelin/axon-related endpoints and functional measures, although mechanistic certainty varies across models. Human evidence remains early but broadly supports safety; a randomized trial in moderate traumatic brain injury reported treatment-related changes in diffusion-MRI WM metrics, while small dementia and chronic-injury studies report heterogeneous cognitive and physiological signals. Given dose dependence and depth-limited transcranial delivery, we synthesize mechanism-informed, dose-aware reporting guidance and WM-anchored outcome frameworks that pair diffusion MRI/DTI with interpretable biomarkers (e.g., NfL, GFAP, sTREM2) and thermally controlled sham designs. We also note potential indirect/systemic contributions that could help reconcile depth-dose constraints with deeper WM effects.
Insights
Near-infrared photobiomodulation (PBM) shows promise for treating white-matter (WM) injury by modulating microglial states and supporting repair. Further research is needed to optimize dosing and delivery for conditions like traumatic brain injury and dementia.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Regenerative Medicine
Background:
- White-matter (WM) injury is a key factor in neurological disorders such as multiple sclerosis, traumatic brain injury, Alzheimer's disease, and small-vessel disease.
- Microglia play a crucial role in the WM injury-to-repair continuum, shifting between inflammatory and repair-competent states.
- Near-infrared photobiomodulation (PBM) targets mitochondrial redox pathways and inflammatory tone, with varying mechanisms depending on wavelength.
Purpose of the Study:
- To explore the potential of PBM in mitigating WM injury and promoting repair.
- To organize WM injury-to-repair logic through microglial state programs.
- To synthesize mechanism-informed, dose-aware reporting guidance for PBM studies.
Main Methods:
- Review of existing literature on PBM effects in demyelination and spinal cord injury models.
- Analysis of PBM mechanisms, particularly wavelength-dependent effects on mitochondrial pathways.
- Synthesis of guidance for outcome frameworks, including diffusion MRI/DTI and biomarkers (NfL, GFAP, sTREM2).
Main Results:
- PBM has demonstrated reductions in inflammatory glial markers and improvements in myelin/axon endpoints in animal models.
- Human evidence suggests PBM is safe, with early trials showing changes in WM metrics and cognitive signals.
- Dose dependence and depth-limited delivery are critical considerations for PBM efficacy.
Conclusions:
- PBM offers a potential therapeutic strategy for WM injury by influencing microglial states and supporting repair processes.
- Standardized reporting and outcome frameworks are essential for advancing PBM research in neurological disorders.
- Further investigation into indirect/systemic effects may help overcome depth-dose limitations for deeper WM targets.
More Related Videos
06:56Near Infrared (NIr) Light Increases Expression of a Marker of Mitochondrial Function in the Mouse Vestibular Sensory Epithelium
Published on: March 14, 2015
12:48In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015